High Commissioner of India visits Wockhardt UK
The High Commissioner was provided with a tour of the vaccine fill-finish facility which is currently contracted by the UK…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Wockhardt
UK government extends contract with Wockhardt to fill-finish COVID-19 vaccines
This expands the original agreement from 18 to 24 months i.e., until August 2022 and the manufacturing will continue to be…
Wockhardt signs partnership with UK Government to fill-finish COVID-19 vaccine
The manufacturing will be undertaken at CP Pharmaceuticals, a subsidiary of Wockhardt based in Wrexham, North Wales
Dr Reddy’s Laboratories completes acquisition of Wockhardt’s select business divisions
The acquired divisions comprise a portfolio of 62 brands in multiple therapy areas such as respiratory, neurology, VMS,…
Wockhardt Q4 results: Firm posts profit of Rs 69 crore after loss in Q4FY19
Consolidated total income of the company stood at Rs 700.66 crore for the quarter under review. It was Rs 866.76 crore in the…
Wockhardt’s QIDP status for WCK 6777 reflects unmet need and untapped market opportunity:…
WCK 6777 targets multidrug resistance bacterial infections where unmet need is high, translating to an untapped market…
Wockhardt receives US FDA Qualified Infectious Disease Product designation for WCK 6777
WCK 6777 is a first-ever once-a-day β-lactam enhancer-class antibiotic
Dr Reddy’s to acquire Wockhardt’s select generics for Rs 1850 crore
The business consists of a portfolio of 62 brands in multiple therapy areas such as respiratory, neurology, VMS, dermatology, pain…
Wockhardt gets DCGI approval for two new antibiotics
EMROK (IV) and EMROK-O (Oral) have got approval for acute bacterial skin and skin structure infections including diabetic foot…
Wockhardt Q1 net loss narrows to Rs 45 crore
The company had posted a net loss of Rs 89.18 crore in the same period a year ago